Kenneth Turteltaub

Kenneth Turteltaub


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
KTKenneth Turteltaub
Kenneth Turteltaub
JVJohn S. Vogel
John S. Vogel
Accelerator mass spectrometry (AMS) is a mass spectrometric method for quantifying isotopes. It has had great impact in the geosciences and is now being applied in the biomedical fields. AMS measures radioisotopes such as 14C, 3H, 41Ca, and 36Cl, and others, with attomole sensitivity and high precision. Its use is allowing absorption, distribution, metabolism and elimination studies, as well as detailed pharmacokinetics, to be carried out directly in humans with very low chemical or radiological hazard. It is used in combination with standard separation methodologies, such as chromatography, in identification of metabolites and molecular targets for both toxicants and pharmacologic agents. AMS allows the use of very low specific activity chemicals ( 1 mCi/mmol), creating opportunities to use compounds not available in a high specific activity form, such as those that must be biosynthesized, produced in combinatorial libraries, or made through inefficient synthesis. AMS is allowing studies to be carried out with agents having low bioavailability, low systemic distributions, or high toxicity where administered doses must be kept low (1 μg/kg). It may have uses in tests for idiosyncratic metabolism, drug interaction, or individual susceptibility, among others. The ability to use very low chemical doses, low radiological doses, small samples and conduct multiple dose studies may help move drug candidates into humans faster and safer than before. The uses of AMS are growing and its potential for drug development is only now beginning to be realized.

1 September 1999 in Cancer Letters
Verified
Journal Article
Closed access
KTKenneth Turteltaub
Kenneth Turteltaub
KDKaren H Dingley
Karen H Dingley
KCKellie D Curtis
Kellie D Curtis
MMMichael A Malfatti
Michael A Malfatti
RTRobert J Turesky
Robert J Turesky
NLNicholas P Lang
Nicholas P Lang

1 May 1997 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
KTKenneth Turteltaub
Kenneth Turteltaub
RMRobert J Mauthe
Robert J Mauthe
KDKaren H Dingley
Karen H Dingley
JVJohn S Vogel
John S Vogel
CFChristopher E Frantz
Christopher E Frantz
NSNancy Shen
Nancy Shen

15 December 2021 in Environment International
Verified
Journal Article
Open access
MMMonica Maier
Monica Maier
LSLisbeth K. Siddens
Lisbeth K. Siddens
JPJamie M. Pennington
Jamie M. Pennington
SUSandra L. Uesugi
Sandra L. Uesugi
KAKim A. Anderson
Kim A. Anderson
DWDavid Williams
David Williams
Benzo[a]pyrene (BaP) is formed by incomplete combustion of organic materials (petroleum, coal, tobacco, etc.). BaP is designated by the International Agency for Research on Cancer as a group 1 known human carcinogen; a classification supported by numerous studies in preclinical models and epidemiology studies of exposed populations. Risk assessment relies on toxicokinetic and cancer studies in rodents at doses 5–6 orders of magnitude greater than average human uptake. Using a dose-response design at environmentally relevant concentrations, this study follows uptake, metabolism, and elimination of [14C]-BaP in human plasma by employing UPLC - accelerator mass spectrometry (UPLC-AMS). Volunteers were administered 25, 50, 100, and 250 ng (2.7–27 nCi) of [14C]-BaP (with interceding minimum 3-week washout periods) with quantification of parent [14C]-BaP and metabolites in plasma measured over 48 hours. [14C]-BaP median Tmax was 30 minutes with Cmax and area under the curve (AUC) approximating dose-dependency. Marked inter-individual variability in plasma pharmacokinetics following a 250 ng dose was seen with 7 volunteers as measured by the Cmax (8.99 ± 7.08 ng × mL−1) and AUC0–48hr (68.6 ± 64.0 fg × hr−1 × mL−1). Approximately 3–6% of the [14C] recovered (AUC0–48 hr) was parent compound, demonstrating extensive metabolism following oral dosing. Metabolite profiles showed that, even at the earliest time-point (30 min), a substantial percentage of [14C] in plasma was polar BaP metabolites. The best fit modeling approach identified non-compartmental apparent volume of distribution of BaP as significantly increasing as a function of dose (p=0.004). Bay region tetrols and dihydrodiols predominated, suggesting not only was there extensive first pass metabolism but also potentially bioactivation. AMS enables the study of environmental carcinogens in humans with de minimus risk, allowing for important testing and validation of physiologically based pharmacokinetic models derived from animal data, risk assessment, and the interpretation of data from high-risk occupationally exposed populations.

1 September 1997 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
AKAntti Kautiainen
Antti Kautiainen
JVJohn S. Vogel
John S. Vogel
KTKenneth Turteltaub
Kenneth Turteltaub

11 October 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
HEHeather A Enright
Heather A Enright
MMMichael A. Malfatti
Michael A. Malfatti
MZMaike Zimmermann
Maike Zimmermann
TOTed Ognibene
Ted Ognibene
PHPaul Henderson
Paul Henderson
KTKenneth Turteltaub
Kenneth Turteltaub